Dr. Steven A. Curley specializes in providing surgical care for patients with hepatobiliary and pancreatic malignancies. As our chief of surgical oncology and cancer center associate director, he leads efforts at Baylor College of Medicine (BCM) and on the McNair campus to build a world-class, multidisciplinary surgical oncology program with significant national and international outreach and stature.
Dr. Curley has been leading a basic sciences laboratory for 22 years. Currently, his research centers on the design, bench testing, and clinical study of novel noninvasive radiofrequency (RF) field treatment devices. Having developed two FDA-approved devices for invasive radiofrequency ablation needles to treat unresectable liver cancers, his current studies focus on targeted delivery of metallic or semiconducting nanoparticles that release heat under RF field induction to cause thermal cytotoxicity in cancer cells. His group has also performed complex physicochemical measurements of nanoparticles, and has conjugated them to antibodies, peptides, and pharmacologic agents to target cancer cells. He hopes to test these novel treatments in human clinical trials at BCM within the next two to three years, pending FDA approval.
- Professor of Surgery and Chief: Division of Surgical Oncology Baylor College of Medicine Houston, United States
- Olga Keith Wiess Chair of Surgery: Baylor College of Medicine
- Associate Director for Clinical Affairs: Dan L Duncan Comprehensive Cancer Center
- Oncology Service Line Chief: CHI St. Luke’s Medical Center
- Professor of Mechanical Engineering and Materials Science: Rice University
- Fellowship from The University of Texas, M.D. Anderson Cancer Center: Houston, Texas, United States
- Residency from University of New Mexico Hospitals: Albuquerque, New Mexico, United States
- M.D. from The University of Texas Medical School at Houston: Houston, Texas, United States
- American Board of Surgery
Honors & Awards
- Top 1% of Physicians: US News & World Report, 2012-2015
- Patients’ Choice Award: America’s Most Compassionate Doctors, 2010-2015
- Best Doctors in America
- America’s Top Doctors: Castle Connolly
- Surgical Oncology
- Liver, bile duct, and gallbladder cancer surgery
- Neuroendocrine tumor surgery
- Colorectal cancer surgery
- American College of Surgeons
- American Society of Clinical Oncology
- Society for Surgery of the Alimentary Tract
- Southwest Oncology Group
- American Hepato-Pancreato-Biliary Association Member, Committee on Emerging Te
- Institute of Medicine National Cancer Policy Forum
- American Association of Cancer Research
- Harris County Medical Society
- Texas Medical Association
- Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. “Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy.” Ann Surg. 2013;257(6):1079-88.
- Corr SJ, Cisneros BT, Green L, Raoof M, Curley SA. “Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy.” J Vis Exp. 2013
- 4. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. “Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.” J Clin Oncol. 2012;30(36):4566-72.
- 3. Sahin IH, Shama MA, Tanaka M, Abbruzzese JL, Curley SA, Hassan M, Li D. “Association of diabetes and perineural invasion in pancreatic cancer.” Cancer Med. 2012;1(3):357-62.
- 2. Raoof M, Corr SJ, Kaluarachchi WD, Massey KL, Briggs K, Zhu C, Cheney MA, Wilson LJ, Curley SA. “Stability of antibody-conjugated gold nanoparticles in the endolysosomal nanoenvironment: Implications for noninvasive radiofrequency-based cancer therapy.” Nanomedicine. 2012;8(7):1096-105.
- 1. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. “Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.” Ann Surg. 2012;256(4):642-650.